LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

13.99

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.99

Max

13.99

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-4.43% downside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	418M 1B
Vorige openingsprijs	13.99
Vorige sluitingsprijs	13.99

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mrt 2026, 23:12 UTC

Populaire aandelen

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mrt 2026, 22:15 UTC

Winsten

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mrt 2026, 21:42 UTC

Belangrijke Nieuwsgebeurtenissen

Stryker Says Cyberattack Disruption Is Continuing

12 mrt 2026, 21:29 UTC

Belangrijke Nieuwsgebeurtenissen

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mrt 2026, 21:27 UTC

Winsten

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mrt 2026, 20:46 UTC

Winsten

Adobe Posts Higher Sales With CEO Set to Depart

12 mrt 2026, 20:21 UTC

Belangrijke Nieuwsgebeurtenissen

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mrt 2026, 23:57 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mrt 2026, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 mrt 2026, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mrt 2026, 22:13 UTC

Winsten

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mrt 2026, 22:13 UTC

Winsten

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mrt 2026, 22:13 UTC

Winsten

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mrt 2026, 22:13 UTC

Winsten

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mrt 2026, 22:13 UTC

Winsten

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mrt 2026, 22:13 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

12 mrt 2026, 22:13 UTC

Marktinformatie

Winsten

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mrt 2026, 21:16 UTC

Acquisities, Fusies, Overnames

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mrt 2026, 21:04 UTC

Winsten

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mrt 2026, 21:02 UTC

Winsten

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mrt 2026, 21:02 UTC

Winsten

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mrt 2026, 21:02 UTC

Winsten

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mrt 2026, 21:02 UTC

Winsten

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mrt 2026, 20:57 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

12 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mrt 2026, 20:10 UTC

Winsten

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mrt 2026, 20:05 UTC

Winsten

Adobe 1Q Rev $6.4B >ADBE

12 mrt 2026, 20:05 UTC

Winsten

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

-4.43% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.38 USD -4.43%

Hoogste 14 USD

Laagste 9 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.